Cited by 204HIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsHIV Research and Treatment

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

Margolis, David A, Brinson, Cynthia C, Smith, Graham H R, de Vente, Jerome, Hagins, Debbie P, Eron, Joseph J, Griffith, Sandy K, Clair, Marty H St, Stevens, Marita C, Williams, Peter E, Ford, Susan L, Stancil, Britt S, Bomar, Melinda M, Hudson, Krischan J, Smith, Kimberly Y, Spreen, William R·2015·The Lancet Infectious Diseases

DOI 10.1016/s1473-3099(15)00152-8

Open this paper in CoChat — free account

Abstract

Background In phase 1 trials, the HIV-1 integrase strand transfer inhibitor cabotegravir (GSK1265744) was well tolerated, both alone, and in combination with the non-nucleoside reverse transcriptase inhibitor rilpivirine. We assessed cabotegravir plus rilpivirine, as a two-drug oral antiretroviral regimen, for the maintenance of viral suppression in antiretroviral-naive HIV-1-infected individuals.Methods In the phase 2b Long-Acting antireTroviral Treatment Enabling (LATTE) trial, a multicentre study done in Canada and the USA, antiretroviral-naive HIV-1-infected adults (aged ≥18 years) were randomly allocated in a 1:1:1:1 ratio to oral cabotegravir 10 mg once a day, 30 mg once a day, 60 mg once a day, or oral efavirenz 600 mg once a day with dual nucleoside reverse transcriptase inhibitors (NRTIs) for 24 weeks of induction. Patients who were virologically suppressed by week 24 received a two-drug maintenance regimen consisting of their randomly allocated cabotegravir dose plus oral rilpivirine 25 mg or continued efavirenz plus NRTIs for an additional 72 weeks. Patients and investigators were masked to doses of cabotegravir received for 96 weeks, but not to the assignment of cabotegravir or efavirenz. The primary endpoint was the proportion of patients with fewer than 50 copies per mL of HIV-1 RNA (US Food and Drug Administration snapshot algorithm) at week 48. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, NCT01641809.Findings Of 243 patients randomly allocated and treated, 156 (86%) of 181 patients in the cabotegravir groups (52 [87%] of 60, 51 [85%] of 60, and 53 [87%] of 61 patients in the 10 mg, 30 mg, and 60 mg groups, respectively) and 46 (74%) of 62 in the efavirenz group had fewer than 50 copies per mL of HIV-1 RNA after induction therapy. After patients in the cabotegravir groups were changed over from dual NRTIs to rilpivirine at week 24, 149 (82%; 95% CI 77-88) patients in the cabotegravir groups (48 [80%; 70-90], 48 [80%; 70-90], and 53 [87%; 78-95] patients in the 10 mg, 30 mg, and 60 mg groups, respectively) versus 44 (71%; 60-82) in the efavirenz group were virologically suppressed at week 48, and 137 (76%; 69-82) receiving cabotegravir (41 [68%; 57-80], 45 [75%; 64-86], and 51 [84%; 74-93] patients in the 10 mg, 30 mg, and 60 mg groups, respectively) versus 39 (63%; 51-75) in the efavirenz group were virologically suppressed at week 96. Treatment-related adverse events were reported by 93 (51%) cabotegravir-treated patients (28 [47%], 32 [53%], and 33 [54%] patients in the 10 mg, 30 mg, and 60 mg groups, respectively) and 42 (68%) efavirenz-treated patients. Six (3%) patients in the cabotegravir groups (one [2%], one [2%], and four [7%] patients in the 10 mg, 30 mg, and 60 mg groups, respectively) withdrew because of treatment-emergent adverse events compared with nine (15%) in the efavirenz group.Interpretation Cabotegravir plus dual NRTI therapy had potent antiviral activity during the induction phase. As a two-drug maintenance therapy, cabotegravir plus rilpivirine provided antiviral activity similar to efavirenz plus dual NRTIs until the end of week 96. Combined efficacy and safety results lend support to our selection of oral cabotegravir 30 mg once a day for further assessment. LATTE precedes studies of the assessment of longacting injectable formulations of both drugs as a two-drug regimen for the treatment of HIV-1 infection.Funding ViiV Healthcare and Janssen Research and Development.

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(15)00152-8

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Walmsley, S. L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215541 · Cited by 876
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
Lennox, J. L., DeJesus, E., Lazzarin, A., Pollard, R. B., Madruga, J. V., Berger, D. S., Zhao, J., Xu, X., Williams‐Diaz, A., Rodgers, A. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60918-1 · Cited by 626
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
Cahn, P. E., Pozniak, A., Mingrone, H., Shuldyakov, A. A., Brites, C. R., Andrade-Villanueva, J. F., Richmond, G. J., Buendia, C. B., Fourie, J., Ramgopal, M. N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61221-0 · Cited by 514
Self-citation
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
Raffi, F., Jaeger, H., Quirós-Roldán, E., Albrecht, H., Belonosova, E., Gatell, J. M., Baril, J.-G., Domingo, P., Brennan, C. A., Almond, S., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70257-3 · Cited by 378
Long-acting injectable antiretrovirals for HIV treatment and prevention
Spreen, W. R., Margolis, D. A., & Pottage, J. C. (2013) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000002 · Cited by 253
Self-citation
Update of the drug resistance mutations in HIV-1: March 2013.
Johnson, V. A., Cálvez, V., Günthard, H. F., Paredes, R., Pillay, D., Shafer, R. W., Wensing, A. M. J., & Richman, D. D. (2013) · Europe PMC (PubMed Central) · Cited by 240
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
Molina, J., LaMarca, A., Andrade-Villanueva, J. F., Clotet, B., Clumeck, N., Liu, Y.-P., Zhong, L., Margot, N., Cheng, A., & Chuck, S. L. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70249-3 · Cited by 170
Dolutegravir in antiretroviral-naive adults with HIV-1
Stellbrink, H.-J., Reynes, J., Lazzarin, A., Voronin, E., Pulido, F., Felizarta, F., Almond, S., Clair, M. S., Flack, N., & Min, S. (2013) · AIDS · doi:10.1097/qad.0b013e3283612419 · Cited by 160
Self-citation
GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects
Spreen, W. R., Ford, S. L., Chen, S., Wilfret, D. A., Margolis, D. M., Gould, E. P., & Piscitelli, S. C. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000301 · Cited by 146
Self-citation
Analyzing Sleep Abnormalities in HIV‐Infected Patients Treated with Efavirenz
Gallego, L., Barreiro, P., Villegas, R. D. R., de Requena, D. G., Albariño, A. R., González‐Lahoz, J., & Soriano, V. (2004) · Clinical Infectious Diseases · doi:10.1086/380791 · Cited by 141

Show all 21 references

Research works printed but not linked: 3

Elion, 2013, A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results, J Acquir Immune Defic Syndr, 63, 494, 10.1097/QAI.0b013e318298469c · DOI
Eron, 2013, Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials, Lancet Infect Dis, 13, 587, 10.1016/S1473-3099(13)70093-8 · DOI
Dudas, 2015, Resistance mutations observed in a study subject on oral two-drug maintenance therapy with 10 mg cabotegravir + 25 mg rilpivirine, Glob Antivir J, 11

Sorted by citations

Approved Antiviral Drugs over the Past 50 Years
Clercq, E. D., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,477
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Günthard, H. F., Saag, M. S., Benson, C. A., del Rı́o, C., Eron, J. J., Gallant, J. E., Hoy, J., Mugavero, M. J., Sax, P. E., Thompson, M., et al. (2016) · JAMA · doi:10.1001/jama.2016.8900 · Cited by 740
Self-citation
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
Swindells, S., Andrade-Villanueva, J. F., Richmond, G. J., Rizzardini, G., Baumgarten, A., Masiá, M., Latiff, G., Pokrovsky, V. V., Bredeek, F., Smith, G. H. R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1904398 · Cited by 603
Self-citation
Nanotechnology approaches for global infectious diseases
Kirtane, A. R., Verma, M., Karandikar, P., Furin, J., Langer, R., & Traverso, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00866-8 · Cited by 520
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
Margolis, D. A., González‐García, J., Stellbrink, H.-J., Eron, J. J., Yazdanpanah, Y., Podzamczer, D., Lutz, T., Angel, J. B., Richmond, G. J., Clotet, B., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31917-7 · Cited by 506
Self-citation
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
Orkin, C. M., Arastéh, K., Hernández-Mora, M. G., Pokrovsky, V. V., Overton, E. T., Girard, P., Oka, S., Walmsley, S. L., Bettacchi, C. J., Brinson, C. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1909512 · Cited by 495
Self-citation
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
Overton, E. T., Richmond, G. J., Rizzardini, G., Jaeger, H., Orrell, C., Идиятулловна, Н. Ф., Bredeek, F., Deltoro, M. G., Swindells, S., Andrade-Villanueva, J. F., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32666-0 · Cited by 380
Self-citation
Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy
Kirtane, A. R., Abouzid, O., Minahan, D., Bensel, T., Hill, A. L., Selinger, C., Bershteyn, A., Craig, M., Mo, S. S., Mazdiyasni, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02294-6 · Cited by 227
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
Markowitz, M. H., Frank, I., Grant, R. M., Mayer, K. H., Elion, R., Goldstein, D. A., Fisher, C., Sobieszczyk, M. E., Gallant, J. E., Tieu, H., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30068-1 · Cited by 217
Self-citation
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
Orkin, C. M., Oka, S., Philibert, P., Brinson, C. C., Bassa, A., Gusev, D. A., Degen, O., González‐García, J., Bernal, E., Tan, D. H. S., et al. (2021) · The Lancet HIV · doi:10.1016/s2352-3018(20)30340-4 · Cited by 179
Self-citation
HIV drug resistance against strand transfer integrase inhibitors
Anstett, K., BRENNER, B. G., Mésplède, T., & Wainberg, M. A. (2017) · Retrovirology · doi:10.1186/s12977-017-0360-7 · Cited by 176
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
Landovitz, R. J., Li, S., Grinsztejn, B. G. J., Dawood, H., Liu, A., Magnus, M., Hosseinipour, M. C., Panchia, R., Cottle, L. M., Chau, G., et al. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002690 · Cited by 184
Self-citation
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
Rizzardini, G., Overton, E. T., Orkin, C. M., Swindells, S., Arastéh, K., Hernández-Mora, M. G., Pokrovsky, V. V., Girard, P., Oka, S., Andrade-Villanueva, J. F., et al. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002466 · Cited by 159
Self-citation
Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy
Owen, A., & Rannard, S. P. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.003 · Cited by 161
Cardiovascular risk and dyslipidemia among persons living with HIV: a review
Maggi, P., Biagio, A. D., Rusconi, S., Cicalini, S., D’Abbraccio, M., d’Ettorre, G., Martinelli, C. V., Nunnari, G., Sighinolfi, L., Spagnuolo, V., et al. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2626-z · Cited by 159
2019 update of the drug resistance mutations in HIV-1.
Wensing, A. M. J., Cálvez, V., Ceccherini‐Silberstein, F., Charpentier, C., Günthard, H. F., Paredes, R., Shafer, R. W., & Richman, D. D. (2019) · PubMed Central · Cited by 144
Long-acting antiretrovirals: a new era for the management and prevention of HIV infection
Thoueille, P., Choong, E., Cavassini, M. L., Buclin, T., & Decosterd, L. A. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab324 · Cited by 148
Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
Hodge, D., Back, D. J., Gibbons, S., Khoo, S., & Marzolini, C. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01005-1 · Cited by 134
Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir
the Montreal Primary HIV (PHI) Cohort Study Group, Oliveira, M., Ibanescu, R.-I., Anstett, K., Mésplède, T., Routy, J., Robbins, M., & BRENNER, B. G. (2018) · Retrovirology · doi:10.1186/s12977-018-0440-3 · Cited by 118
Long-Acting HIV Drugs for Treatment and Prevention
Gulick, R. M., & Flexner, C. W. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-041217-013717 · Cited by 119
The promise and pitfalls of long-acting injectable agents for HIV prevention
Landovitz, R. J., Kofron, R., & McCauley, M. (2016) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000219 · Cited by 110
Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs
Smith, S. J., Zhao, X. Z., Passos, D. O., Lyumkis, D., Burke, T. R., & Hughes, S. H. (2021) · Viruses · doi:10.3390/v13020205 · Cited by 110
Update on Adverse Effects of HIV Integrase Inhibitors
Kołakowska, A., Maresca, A. F., Collins, I. J., & Cailhol, J. (2019) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-019-00203-7 · Cited by 104
A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus
Thompson, M., Saag, M. S., DeJesus, E., Gathe, J., Lalezari, J. P., LANDAY, A. L., Cade, J. L., Enejosa, J., Lefebvre, E. A., & Feinberg, J. (2015) · AIDS · doi:10.1097/qad.0000000000000988 · Cited by 91
Two-drug regimens for HIV treatment
Gibas, K. M., Kelly, S. G., Arribas, J. R., Cahn, P. E., Orkin, C. M., Daar, E. S., Sax, P. E., & Taiwo, B. (2022) · The Lancet HIV · doi:10.1016/s2352-3018(22)00249-1 · Cited by 80
A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
Bares, S. H., & Scarsi, K. K. (2021) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000708 · Cited by 77
Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort
Sension, M., Brunet, L., Hsu, R. K., Fusco, J. S., Cochran, Q., Uranaka, C., Sridhar, G., Vannappagari, V. X., Wyk, J. A. V., McCurdy, L., et al. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-023-00890-2 · Cited by 66
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study
Smith, G. H. R., Henry, W. K., Podzamczer, D., Masiá, M. D. M., Bettacchi, C. J., Arastéh, K., Jaeger, H., Khuong-Josses, M.-A., Montes-Ramírez, M. L., Stellbrink, H., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab439 · Cited by 64
Self-citation
Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland
Thoueille, P., Saldanha, S. A., Schaller, F., Choong, E., Munting, A., Cavassini, M. L., Braun, D. L., Günthard, H. F., Kusejko, K., Surial, B., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100793 · Cited by 63
A Review of HIV Pre-Exposure Prophylaxis: The Female Perspective
Bailey, J. L., Molino, S., Vega, A. D., & Badowski, M. E. (2017) · Infectious Diseases and Therapy · doi:10.1007/s40121-017-0159-9 · Cited by 62
Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
Fernandez, C., & van Halsema, C. L. (2019) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s184642 · Cited by 60
Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review
Podany, A. T., Scarsi, K. K., Pham, M. M., & Fletcher, C. V. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00898-8 · Cited by 60
Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects
Han, K., Baker, M., Lovern, M., Paul, P., Xiong, Y., Patel, P., Moore, K. P., Seal, C., Cutrell, A. G., D'Amico, R. D., et al. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15439 · Cited by 59
Self-citation
Long-Acting Antiretrovirals: Where Are We now?
Nyaku, A. N., Kelly, S. G., & Taiwo, B. (2017) · Current HIV/AIDS Reports · doi:10.1007/s11904-017-0353-0 · Cited by 59
Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?
Brooks, K. M., Sherman, E. M., Egelund, E. F., Brotherton, A. L., Durham, S. H., Badowski, M. E., & Cluck, D. B. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2246 · Cited by 57
Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis
Achhra, A. C., Mwasakifwa, G. E., Amin, J., & Boyd, M. A. (2016) · The Lancet HIV · doi:10.1016/s2352-3018(16)30015-7 · Cited by 56
Dual antiretroviral therapy for HIV infection
Soriano, V., Fernández-Montero, J. V., Benítez‐Gutiérrez, L., de Mendoza, C., Arias, A., Barreiro, P., Peña, J. M., & Labarga, P. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1343300 · Cited by 56
Cabotegravir Plus Rilpivirine: First Approval
Markham, A. (2020) · Drugs · doi:10.1007/s40265-020-01326-8 · Cited by 54
HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors
Koneru, P. C., Francis, A. C., Deng, N., Rebensburg, S. V., Hoyte, A. C., Lindenberger, J., Adu-Ampratwum, D., Larue, R. C., Wempe, M. F., Engelman, A. N., et al. (2019) · eLife · doi:10.7554/elife.46344 · Cited by 49
Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV
Taki, E., Soleimani, F., Asadi, A., Ghahramanpour, H., Namvar, A., & Heidary, M. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2022.2081153 · Cited by 51
Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments
Achhra, A. C., Nugent, M. M., Mocroft, A., Ryom, L., & Wyatt, C. M. (2016) · Current HIV/AIDS Reports · doi:10.1007/s11904-016-0315-y · Cited by 49
Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution
Kevadiya, B. D., Woldstad, C., Ottemann, B. M., Dash, P. K., Sajja, B. R., Lamberty, B. G., Morsey, B., Kocher, T., Dutta, R., Bade, A. N., et al. (2017) · Theranostics · doi:10.7150/thno.22764 · Cited by 51
Anti-retroviral drugs: current state and development in the next decade
Zhang, X. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.01.012 · Cited by 49
Treatment and prevention of HIV infection with long-acting antiretrovirals
Benítez‐Gutiérrez, L., Soriano, V., Requena, S., Arias, A., Barreiro, P., & de Mendoza, C. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1453805 · Cited by 50
Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries
Akinwunmi, B. O., Buchenberger, D., Scherzer, J., Bode, M., Rizzini, P., Vecchio, F., Roustand, L., Nachbaur, G., Finkielsztejn, L., Chounta, V., et al. (2021) · Sexually Transmitted Infections · doi:10.1136/sextrans-2020-054648 · Cited by 49
Advances in Long-Acting Agents for the Treatment of HIV Infection
Rana, A., Castillo‐Mancilla, J., Tashima, K. T., & Landovitz, R. J. (2020) · Drugs · doi:10.1007/s40265-020-01284-1 · Cited by 48
Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
Ford, S. L., Sutton, K., Lou, Y., Zhang, Z., Tenorio, A., Trezza, C., Patel, P., & Spreen, W. R. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00487-17 · Cited by 46
Self-citation
Creation of a Long-Acting Nanoformulated 2′,3′-Dideoxy-3′-Thiacytidine
Guo, D., Zhou, T., Araínga, M., Palandri, D. L., Gautam, N., Bronich, T. K., Alnouti, Y., McMillan, J., Edagwa, B., & Gendelman, H. E. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001170 · Cited by 43
Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date
Whitfield, T., Torkington, A., & van Halsema, C. (2016) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s97920 · Cited by 43
Recent Advances in the Development of Integrase Inhibitors for HIV Treatment
Trivedi, J. S., Mahajan, D., Jaffe, R. J., Acharya, A., Mitra, D., & Byrareddy, S. N. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-019-00480-3 · Cited by 50
Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1
Hassounah, S. A., Alikhani, A., Oliveira, M., Bharaj, S., Ibanescu, R.-I., Osman, N., Xu, H.-T., Brenner, B. G., Mesplède, T., & Wainberg, M. A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01695-17 · Cited by 40
Advancements in nano-enabled therapeutics for neuroHIV management
Kaushik, A. K., Jayant, R. D., & Nair, M. G. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s109943 · Cited by 41
Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251
Andrews, C. D., Bernard, L. S., Poon, A. Y., Mohri, H., Gettie, N., Spreen, W. R., Gettie, A., Russell‐Lodrigue, K., Blanchard, J., Hong, Z., et al. (2016) · AIDS · doi:10.1097/qad.0000000000001343 · Cited by 41
Self-citation
Long-acting parenteral combination antiretroviral loaded nano-drug delivery system to treat chronic HIV-1 infection: A humanized mouse model study
Mandal, S., Kang, G., Prathipati, P. K., Fan, W., Li, Q., & Destache, C. J. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.06.005 · Cited by 40
Rilpivirine long-acting for the prevention and treatment of HIV infection
Ferretti, F., & Boffito, M. (2018) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000474 · Cited by 40
The Promise of Long-Acting Antiretroviral Therapies: From Need to Manufacture
Gendelman, H. E., McMillan, J., Bade, A. N., Edagwa, B., & Kevadiya, B. D. (2019) · Trends in Microbiology · doi:10.1016/j.tim.2019.02.009 · Cited by 39
Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients
Rossetti, B., Montagnani, F., & Luca, A. D. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1457648 · Cited by 37
Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase
Singh, K. D., Sarafianos, S. G., & Sönnerborg, A. B. (2019) · Pharmaceuticals · doi:10.3390/ph12020062 · Cited by 37
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy
Mills, A., Richmond, G. J., Newman, C. L., Osiyemi, O. O., Cade, J. L., Brinson, C. C., Vente, J. D., Margolis, D. A., Sutton, K., Wilches, V., et al. (2021) · AIDS · doi:10.1097/qad.0000000000003085 · Cited by 36
Self-citation
Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection
Radzio‐Basu, J., Cong, M., Ruone, S. J., Newton, A., Wei, X., Mitchell, J. M., Ellis, S., Petropoulos, C. J., Huang, W., Spreen, W. R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10047-w · Cited by 35
Self-citation
Virological History Predicts Non-sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy, Independent of Pharmacokinetic Parameters
Gutiérrez, F., Fernández‐González, M., Ledesma, C., Losada-Echeberría, M., Barrajón‐Catalán, E., García‐Abellán, J., Stefano, D. D., López, L., Belló-Pérez, M., Padilla, S., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae475 · Cited by 35
Long-acting injectable therapy
D'Amico, R. D., & Margolis, D. A. (2019) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000606 · Cited by 34
Self-citation
Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures
Thoueille, P., Cavassini, M. L., Guidi, M., Buclin, T., Girardin, F. R., Decosterd, L. A., & Marzolini, C. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae023 · Cited by 32
Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1
McPherson, T. D., Sobieszczyk, M. E., & Markowitz, M. H. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1460357 · Cited by 32
90‐90‐90 – Charting a steady course to end the paediatric HIV epidemic
Abrams, E. J., & Strasser, S. (2015) · Journal of the International AIDS Society · doi:10.7448/ias.18.7.20296 · Cited by 31
Universal antiretroviral regimens
Jacobson, J. M., & Flexner, C. W. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000374 · Cited by 31
In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents
Rajoli, R. K. R., Back, D. J., Rannard, S. P., Meyers, C. L. F., Flexner, C. W., Owen, A., & Siccardi, M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0557-x · Cited by 31
“I feel empowered”: women’s perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain
Mantsios, A. R., Murray, M. I., Karver, T. S., Davis, W., Margolis, D. M., Kumar, P. N., Swindells, S., Bredeek, U. F., Deltoro, M. G., Rubio, R., et al. (2020) · Culture Health & Sexuality · doi:10.1080/13691058.2020.1752397 · Cited by 30
Self-citation
Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
Himmel, D. M., & Arnold, E. (2020) · Pharmaceuticals · doi:10.3390/ph13060122 · Cited by 30
Cabotegravir-Rilpivirine: The First Complete Long-Acting Injectable Regimen for the Treatment of HIV-1 Infection
Durham, S. H., & Chahine, E. B. (2021) · Annals of Pharmacotherapy · doi:10.1177/1060028021995586 · Cited by 29
Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV
Neyens, M., Crauwels, H. M., Ruixo, J. J. P., & Rossenu, S. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab338 · Cited by 27
A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain
Hingrat, Q. L., Collin, G., Lê, M., Peytavin, G., Visseaux, B., Bertine, M., Tubiana, R., Karmochkine, M., Valin, N., Collin, F., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy940 · Cited by 28
Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravir
Rhee, S., Parkin, N. T., Harrigan, P. R., Holmes, S., & Shafer, R. W. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105427 · Cited by 28
Real-world data on long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror Phase 3 results
Serris, A., Ferré, V. M., Hingrat, Q. L., Bachelard, A., Charpentier, C., Exarchopoulos, M., Damond, F., Phung, B.-C., Landman, R., Yazdanpanah, Y., et al. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae308 · Cited by 25
Dose-related and contextual aspects of suboptimal adherence to antiretroviral therapy among persons living with HIV in Western Europe
Akinwunmi, B. O., Buchenberger, D., Scherzer, J., Bode, M., Rizzini, P., Vecchio, F., Roustand, L., Nachbaur, G., Finkielsztejn, L., Chounta, V., et al. (2020) · European Journal of Public Health · doi:10.1093/eurpub/ckaa229 · Cited by 25
Therapeutic review of cabotegravir/rilpivirine long‐acting antiretroviral injectable and implementation considerations at an HIV specialty clinic
Howe, Z., Norman, S. M., Lueken, A. F., Huesgen, E. C., Farmer, E. K., Jarrell, K., Mathis, J. E., Bonham, K. W., & Hahn, J. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2605 · Cited by 25
Placental transfer of the integrase strand inhibitors cabotegravir and bictegravir in the ex-vivo human cotyledon perfusion model
Pencolé, L., Lê, M., Bouchet-Crivat, F., Duro, D., Peytavin, G., & Mandelbrot, L. (2020) · AIDS · doi:10.1097/qad.0000000000002637 · Cited by 25
Two-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy
Corado, K., Caplan, M. R., & Daar, E. S. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s140767 · Cited by 24
Current and future contraceptive options for women living with HIV
Patel, R. C., Bukusi, E. A., & Baeten, J. M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1378345 · Cited by 24
HIV drug resistance in a cohort of HIV-infected MSM in the United States
Fogel, J. M., Владимировна, С. М., Cummings, V., Wilson, E., Hart, S., Gamble, T., Laeyendecker, O. B., Fernández, R. E., del Rı́o, C., Batey, D. S., et al. (2019) · AIDS · doi:10.1097/qad.0000000000002394 · Cited by 24
Long-acting injectable antiretroviral therapy: will it change the future of HIV treatment?
Brizzi, M. B., Pérez, S. E., Michienzi, S. M., & Badowski, M. E. (2023) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361221149773 · Cited by 24
Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA ‐B*5701 Screening as a Risk‐Mitigation Measure
Stainsby, C. M., Perger, T., Vannappagari, V. X., Mounzer, K., Hsu, R. K., Henegar, C., Oyee, J., Urbaityte, R., Lane, C. E., Carter, L. M., et al. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2196 · Cited by 23
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Adults With Severe Renal Impairment and Healthy Matched Control Participants
Parasrampuria, R., Ford, S. L., Lou, Y., Fu, C., Bakshi, K. K., Tenorio, A. R., Trezza, C., Spreen, W. R., & Patel, P. (2019) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.664 · Cited by 23
Self-citation
Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland
Thoueille, P., Saldanha, S. A., Schaller, F., Munting, A., Cavassini, M. L., Braun, D. L., Günthard, H. F., Kusejko, K., Surial, B., Furrer, H., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081588 · Cited by 22
In VitroAntiviral Activity of Cabotegravir against HIV-2
Smith, R. A., Wu, V. H., Zavala, C. G., Raugi, D. N., Ba, S., Seydi, M., & Gottlieb, G. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01299-18 · Cited by 22
Treatment aspirations and attitudes towards innovative medications among people living with HIV in 25 countries
Rios, P. D. L., Okoli, C., Young, B., Allan, B., Castellanos, E., Brough, G., Eremin, A., Corbelli, G. M., Hardy, W. D., & de Velde, N. V. (2020) · Population Medicine · doi:10.18332/popmed/124781 · Cited by 22
Investigational HIV integrase inhibitors in phase I and phase II clinical trials
Han, Y.-S., Mésplède, T., & Wainberg, M. A. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1378643 · Cited by 21
Why Do We Need New Drug Classes for HIV Treatment and Prevention?
Waheed, A., & Tachedjian, G. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616999151013124606 · Cited by 19
Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors
Yoshinaga, T., Seki, T., Miki, S., Miyamoto, T., Suyama, A., Kawauchi, S., Kobayashi, M., Sato, A., Stewart, E. L., Underwood, M., et al. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.01.013 · Cited by 21
Optimizing Antiretroviral Therapy in Treatment-Experienced Patients Living with HIV: A Critical Review of Switch and Simplification Strategies. An Opinion of the HIV Practice and Research Network of the American College of Clinical Pharmacy
Chastain, D. B., Badowski, M. E., Huesgen, E. C., Pandit, N. S., Pallotta, A. M., & Michienzi, S. (2019) · Journal of the International Association of Providers of AIDS Care (JIAPAC) · doi:10.1177/2325958219867325 · Cited by 20
Getting to 90-90-90 in paediatric HIV: What is needed?
Davies, M., Pinto, J., & Bras, M. (2015) · Journal of the International AIDS Society · doi:10.7448/ias.18.7.20770 · Cited by 42
Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?
Kelly, S. G., Nyaku, A. N., & Taiwo, B. (2016) · Drugs · doi:10.1007/s40265-016-0553-8 · Cited by 20
Pharmacokinetic and Chemical Synthesis Optimization of a Potent d -Peptide HIV Entry Inhibitor Suitable for Extended-Release Delivery
Redman, J. S., Francis, J. N., Marquardt, R., Papac, D. I., Mueller, A. L., Eckert, D. M., Welch, B. D., & Kay, M. S. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b01004 · Cited by 20
Modern Human Immunodeficiency Virus Therapy: Progress and Prospects
Flexner, C. W. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1284 · Cited by 20
Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
Ford, S. L., Lou, Y., Lewis, N. M., Kostapanos, M. S., D'Amico, R. D., Spreen, W. R., & Patel, P. (2018) · Antiviral Therapy · doi:10.3851/imp3306 · Cited by 19
Self-citation
A patient-centred approach to deprescribing antiretroviral therapy in people living with HIV
Guaraldi, G., Milić, J., Marcotullio, S., & Mussini, C. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa329 · Cited by 20
Long-acting injectable HIV therapies: the next frontier
Thornhill, J. P., & Orkin, C. M. (2020) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000701 · Cited by 23
New Strategies of ARV: the Road to Simplification
Buckley, R. D. M., Montejano, R., Stella-Ascariz, N., & Arribas, J. R. (2018) · Current HIV/AIDS Reports · doi:10.1007/s11904-018-0371-6 · Cited by 19
Neuropsychiatric events and dolutegravir in HIV patients
Kheloufi, F., Boucherie, Q., Blin, O. J., & Micallef, J. (2017) · AIDS · doi:10.1097/qad.0000000000001557 · Cited by 18
A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Patients With Hepatic Impairment and Healthy Matched Controls
Shaik, J. S., Ford, S. L., Lou, Y., Zhang, Z., Bakshi, K. K., Tenorio, A. R., Trezza, C., Spreen, W. R., & Patel, P. (2019) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.655 · Cited by 18
Self-citation

Authors: Margolis, D. A., Brinson, C. C., Smith, G. H. R., de Vente, J., Hagins, D. P., Eron, J. J., Griffith, S. K., Clair, M. H. S., Stevens, M. C., Williams, P. E., Ford, S. L., Stancil, B. S., Bomar, M. M., Hudson, K. J., Smith, K. Y., & Spreen, W. R.
Affiliations: GlaxoSmithKline (United States) (US)
Maple Leaf Medical Clinic (CA)
University of North Carolina at Chapel Hill (US)
Janssen (Belgium) (BE)
Corresponding author: Margolis, David A
ORCID: Brinson, Cynthia C
Smith, Graham H R
Hagins, Debbie P
Eron, Joseph J
Griffith, Sandy K
Stevens, Marita C
Smith, Kimberly Y
Spreen, William R
Venue: The Lancet Infectious Diseases
Publisher: Elsevier BV
Published: 2015-10
Volume: 15
Issue: 10
Pages: 1145-1155
ISSN: 1473-3099 (ISSN-L)
DOI: 10.1016/s1473-3099(15)00152-8
OpenAlex: W1674196795
Cited by: 204
References: 21
Citations by year: 2026: 8 · 2025: 13 · 2024: 12 · 2023: 8 · 2022: 14 · 2021: 22 · 2020: 24 · 2019: 18 · 2018: 27 · 2017: 30 · 2016: 20 · 2015: 8
FWCI: 22.09
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Infectious Diseases (publishedVersion)
PubMed (publishedVersion)
Funders: Janssen Research and Development
Topics: Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords: cabotegravir, rilpivirine, HIV-1 infection, long-acting antiretroviral therapy, integrase strand transfer inhibitors, efavirenz, nucleoside reverse transcriptase inhibitors, antiretroviral-naive adults, viral suppression, once-daily dosing, dose-ranging, induction regimens
MeSH terms: Rilpivirine, Adolescent, Adult, Aged, Canada, Double-Blind Method, Female, Humans, Male, Middle Aged, Pyridones, United States, HIV-1, HIV Infections, Treatment Outcome, Reverse Transcriptase Inhibitors, Viral Load, Antiretroviral Therapy, Highly Active, Anti-Retroviral Agents, Diketopiperazines, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks